Mistral Pharma Inc.
TSX VENTURE : MIP

Mistral Pharma Inc.

November 04, 2005 09:26 ET

Mistral Pharma's ABSORPEP'TM' Technology Presented at the 2005 AAPS Meeting

MONTREAL, QUEBEC--(CCNMatthews - Nov. 4, 2005) - Mistral Pharma Inc. (TSX VENTURE:MIP) announced today that its ABSORPEP™ technology would be presented through two poster presentations at the American Association of Pharmaceutical Scientists annual meeting held in Nashville from November 6th to November 11th, 2005.

The two posters are entitled "Development of a reverse polymeric micelle formulation for the oral delivery of therapeutic peptides" and "Synthesis of Alkylated Star-shaped Poly(glycerolmethacrylate)" and will be presented by Marie-Christine Jones and Pankaj Tewari, both graduate students of Pr. Jean-Christophe Leroux from the Canada Research Chair in Drug Delivery, Faculty of Pharmacy of University of Montreal.

The ABSORPEP™ system consists in co-polymers that self-assemble in a supramolecular structure when dispersed in an organic medium. ABSORPEP™ is being developed to be used as an oral absorption system for peptides and proteins which are currently being administered using the intravenous, intra-muscular or subcutaneous routes.
About Mistral Pharma Inc.

Mistral Pharma is an emerging oral drug delivery company which develops generic and branded controlled-delivery products using its PROCISE™, SAVIT™ and CHRONOP™ geometry surface area technologies. These technologies offer many competitive advantages including flexible and fast development, competitive cost of goods and the use of "generally recognized as safe" excipients. Additional information about Mistral Pharma can be obtained on Mistral Pharma's website at www.mistralpharma.com

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • Mistral Pharma Inc.
    Bertrand F. Bolduc, B.Pharm., MBA
    President & Chief Executive Officer
    (514) 920-0909 # 24
    bbolduc@mistralpharma.com
    or
    Mistral Pharma Inc.
    Alain Provencher, CA
    Vice-president, Finance & Chief Financial Officer
    (514) 920-0909 # 22
    aprovencher@mistralpharma.com